Vitrectomy for Diabetic Macular Traction and Edema Associated with Posterior Hyaloidal Traction

doi:10.1016/S0161-6420(92)31901-3

Ophthalmology

Volume 99, Issue 5, May 1992, Pages 753-759

https://doi.org/10.1016/S0161-6420(92)31901-3 Get rights and content

Pars plana vitrectomy with separation of the posterior hyaloid was performed in 10 eyes with diabetic macular edema and traction associated with a thickened and taut premacular posterior hyaloid. Nine of the 10 eyes had previous macular photocoagulation. Preoperative fluorescein angiography showed a deep and diffuse pattern of leakage in the macula. Intraoperatively, the attached and thickened posterior hyaloid was lifted and separated from the retina. Postoperatively, vision improved in nine eyes. The macular traction and edema resolved in eight eyes and decreased in two. Complications included a vitreous hemorrhage, a rhegmatogenous retinal detachment, cataract formation, and a mild epimacular membrane, each occurring in one eye. Vitreous surgery can improve the visual prognosis of some eyes with diabetic macular traction and edema associated with a thickened and taut posterior hyaloid.

References (18)

R Klein et al.
The Wisconsin epidemiologic study of diabetic retinopathy, IV, Diabetic macular edema
Ophthalmology
(1984)
FP Nasrallah et al.
The role of the vitreous in diabetic macular edema
Ophthalmology
(1988)
CL Schepens et al.
Role of the vitreous in cystoid macular edema
Surv Ophthalmol
(1984)
CL Schepens
Fundus changes caused by alterations in the vitreous body
Am J Ophthalmol
(1955)
Photocoagulation for diabetic macular edema, Early Treatment Diabetic Retinopathy Study report number 1
Arch Ophthalmol
(1985)
HR McDonald et al.
Macular edema following panretinal photocoagulation
Retina
(1985)
J Cristiansson
Changes in mucopolysaccharides during alloxan diabetes in the rabbit, I, Comparative studies on serum and the hyaluronic acid of the vitreous body
Acta Ophthalmol
(1958)
JG Cunha-Vaz et al.
Detection of early retinal changes in diabetes by vitreous fluorophotometry
Diabetes
(1979)
S-E Bursell et al.
Vitreous fluorophotometric evaluation of diabetics
Invest Ophthalmol Vis Sci
(1984)

There are more references available in the full text version of this article.

Cited by (593)

Evaluating the effect of vitreomacular interface abnormalities on anti-vascular endothelial growth factor treatment outcomes in diabetic macular edema by optical coherence tomography: A systematic review and meta-analysis
2023, Photodiagnosis and Photodynamic Therapy
To evaluate the effect of vitreomacular interface (VMI) configuration on treatment outcomes after intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME) using optical coherence tomography (OCT).
A systematic literature search was performed on PubMed, Embase, web of science and clinicaltrials.gov. The primary outcome parameters were central macular thickness (CMT), best-corrected visual acuity (BCVA) and mean injection numbers. We performed this meta-analysis by Review Manager (RevMan) 5.4.1.
The impact of epiretinal membrane (ERM), vitreomacular traction (VMT) and vitreomacular adhesion (VMA) on the treatment outcomes were analyzed separately. 9 clinical studies involving 699 eyes were eligible for the meta-analysis for evaluating the effect of ERM/VMT on efficacy. And 7 studies with 610 eyes were included to access whether VMA affected the response to anti-VEGF therapy in patients with DME. The ERM/VMT group had poorer CMT reductions than the control group at 1 month ([MD] 52.91 mm, P<0.00001), while no significant difference at 3 months ([MD] 43.95 mm, P = 0.22) and over 12 months ([MD] 30.51 mm, P = 0.45). No statistically significant difference in the mean BCVA change at 1 month ([MD] -0.03 Log MAR, P = 0.79), whereas ERM/VMT group had poor visual acuity gains at 3 months ([MD] 0.08 Log MAR, P = 0.003), and a tendency of poor vision improvement over 12 months follow-up ([MD] 0.07 Log MAR, P = 0.11). There was no significant difference in the visual and anatomical results over 3 months in DME patients with or without VMA ([MD] -21.92 mm, P = 0.09; [MD] 1.79 letters, P = 0.22). Besides, VMI configuration was not found to affect mean injection numbers.
The limited evidence suggested that ERM/VMT was associated with worse CMT reduction at 1 month, poor BCVA gain at 3 months and a tendency of limited vision improvement over 12 months follow-up in DME patients treated with anti-VEGF agents. And VMA may not adversely affect the anatomic and functional outcomes. However, the results of this meta-analysis should be interpreted with caution because of the heterogeneity among study designs.
Considerations When Offering Minimally Proven Investigational Treatments
2023, Ophthalmology
Persistent diabetic macular edema: Definition, incidence, biomarkers, and treatment methods
2023, Survey of Ophthalmology
Intravitreal antivascular endothelial growth factor (anti-VEGF) treatment has drastically improved the visual and anatomical outcomes in patients with diabetic macular edema (DME); however, success is not always guaranteed, and a proportion of these eyes demonstrate persistent DME (pDME) despite intensive treatment. While standardized criteria to define these treatment-resistant eyes have not yet been established, many studies refer to eyes with no clinical response or an unsatisfactory partial response as having pDME. A patient is considered to have pDME if the retinal thickness improves less than 10–25% after 6 months of treatment. A range of treatment options have been recommended for eyes with pDME, including switching anti-VEGF agents, using corticosteroids and/or antioxidant drugs in adjunct with anti-VEGF therapy, and vitrectomy. In addition, multimodal imaging of DME eyes may be advantageous in predicting the responsiveness to treatment; this is beneficial when initiating alternative therapies. We explore the literature on persistent DME regarding its defining criteria, incidence, the baseline biological markers that may be useful in anticipating the response to treatment, and the available treatment options.
Effectiveness of intravitreal ranibizumab for diabetic macular edema in vitrectomized versus non-vitrectomized eyes: A Meta-analysis
2024, International Journal of Ophthalmology
Effect of aflibercept combined with triamcinolone acetonide on aqueous humor growth factor and inflammatory mediators in diabetic macular edema
2024, International Journal of Ophthalmology
A Review on Diabetic Retinopathy
2024, Current Diabetes Reviews

View all citing articles on Scopus

: Presented at the American Academy of Ophthalmology Annual Meeting, Anaheim, October 1991.

: Supported in part by the Charles Kenneth Feldman Fund, Los Angeles, California, and a Research to Prevent Blindness Award, New York, New York (Dr. Lewis).

¹: Jules Stein Eye Institute and the Department of Ophthalmology, UCLA School of Medicine, Los Angeles

²: The Eye Institute of the Medical College of Wisconsin, Milwaukee

³: William Beaumont Hospital, Royal Oak

⁴: Dr. Campo is currently in private practice in Phoenix.

View full text

Vitrectomy for Diabetic Macular Traction and Edema Associated with Posterior Hyaloidal Traction

Ophthalmology

Ophthalmology

Surv Ophthalmol

Am J Ophthalmol

Photocoagulation for diabetic macular edema, Early Treatment Diabetic Retinopathy Study report number 1

Arch Ophthalmol

Macular edema following panretinal photocoagulation

Retina

Changes in mucopolysaccharides during alloxan diabetes in the rabbit, I, Comparative studies on serum and the hyaluronic acid of the vitreous body

Acta Ophthalmol

Detection of early retinal changes in diabetes by vitreous fluorophotometry

Diabetes

Vitreous fluorophotometric evaluation of diabetics

Invest Ophthalmol Vis Sci